The effects of cAMP-elevating agents, N6-2'-O-dibutyryl cAMP (Bu2cAMP), and glucocorticoid (dexamethasone) on the production of inflammatory mediators--nitric oxide and interleukin-12 (IL-12) and anti-inflammatory mediator interleukin-10 (IL-10) were demonstrated in murine peritoneal macrophages. Inducible nitric oxide synthase (iNOS) and iNOS mRNA were detected by northern blot and western blot, respectively. The cAMP elevating agents Bu2cAMP and prostaglandin E2 each alone did not show any effect on NO production but along with IFN-gamma and lipolysaccharide (LPS) they slightly enhanced NO production. Dexamethasone inhibited NO production in IFN-gamma- and LPS-treated cells; cAMP elevating agents interfered with the NO production inhibited by dexamethasone. Inhibition was revealed at the mRNA level as well as at protein level. Bu2cAMP or dexamethasone either alone or synergistically inhibited IL-12 production; Bu2cAMP interfered with dexamethasone-mediated inhibition of IL-10 production in IFN-gamma- and LPS-treated macrophages. The use of glucocorticoids along with cAMP elevating agents was beneficial in lowering the level of inflammatory mediator IL-12 and producing high levels of the anti-inflammatory mediator IL-10 active in cell protection. On the other hand, interference of Bu2cAMP with dexamethasone-mediated NO inhibition may have adverse effect. Therefore, adverse effects due to cAMP-mediated interference (inhibition) with NO synthesis may occur in many inflammatory diseases during combined drug therapy by glucocorticoids and cAMP elevating agents.

Institute of Microbial Technology Council of Scientific and Industrial Research Chandigarh 160 036 India

Zobrazit více v PubMed

Annu Rev Immunol. 1993;11:165-90 PubMed

J Immunol. 1997 Jan 15;158(2):897-904 PubMed

Biochem Biophys Res Commun. 1995 Nov 13;216(2):438-46 PubMed

Eur J Immunol. 1991 Oct;21(10):2489-94 PubMed

FASEB J. 1991 Sep;5(12):2652-60 PubMed

FEMS Microbiol Lett. 1996 Jul 1;140(2-3):171-8 PubMed

J Interferon Cytokine Res. 2001 Mar;21(3):147-55 PubMed

Biochem Biophys Res Commun. 1993 Sep 15;195(2):1134-8 PubMed

Pharmacol Rev. 1991 Jun;43(2):109-42 PubMed

Folia Microbiol (Praha). 2001;46(3):259-64 PubMed

Cell Immunol. 1995 Apr 15;162(1):1-7 PubMed

Eur J Pharmacol. 1994 Jan 15;266(2):125-9 PubMed

Anal Biochem. 1987 Apr;162(1):156-9 PubMed

J Immunol. 1998 Mar 1;160(5):2231-7 PubMed

J Biol Chem. 1998 Feb 27;273(9):5073-80 PubMed

J Infect Dis. 1997 Apr;175(4):1008-11 PubMed

Folia Microbiol (Praha). 2000;45(5):457-63 PubMed

Eur J Immunol. 1993 Jul;23(7):1711-4 PubMed

Br J Pharmacol. 1999 Jul;127(5):1195-205 PubMed

Trends Pharmacol Sci. 1993 Dec;14(12):436-41 PubMed

Cell Immunol. 1997 Jul 10;179(1):41-7 PubMed

Folia Microbiol (Praha). 2001;46(4):353-8 PubMed

J Biol Chem. 1997 Mar 21;272(12):7786-91 PubMed

J Exp Med. 1998 Nov 2;188(9):1603-10 PubMed

Folia Microbiol (Praha). 2001;46(4):345-51 PubMed

Br J Pharmacol. 1994 May;112(1):1-8 PubMed

Trends Pharmacol Sci. 1992 Jan;13(1):20-3 PubMed

Immunology. 1997 Jul;91(3):361-8 PubMed

Nitric oxide plays a role as second messenger in the ultraviolet-B irradiated green alga Chlorella pyrenoidosa

Lipopolysaccharide-mediated protection against Klebsiella pneumoniae-induced lobar pneumonia: intranasal vs. intramuscular route of immunization

Expression of inflammatory markers in pig amnion after intraamniotic infection with nonpathogenic or enteropathogenic Escherichia coli

Quantitative aspects of lipopolysaccharide and cytokine requirements to generate nitric oxide in macrophages from LPS-hyporesponsive (Lps(d)) C3H/HeJ mice

Nitric oxide alleviates oxidative damage in the green alga Chlorella pyrenoidosa caused by UV-B radiation